DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Copaxone (Glatiramer Acetate) - Published Studies

 
 



Copaxone Related Published Studies

Well-designed clinical trials related to Copaxone (Glatiramer)

Neuroprotection with glatiramer acetate: evidence from the PreCISe trial. [2013]

Interferon beta-1b and glatiramer acetate effects on permanent black hole evolution. [2011.04.05]

Phase III dose-comparison study of glatiramer acetate for multiple sclerosis. [2011.01]

Tolerability and safety of novel half milliliter formulation of glatiramer acetate for subcutaneous injection: an open-label, multicenter, randomized comparative study. [2010.11]

Continuous long-term immunomodulatory therapy in relapsing multiple sclerosis: results from the 15-year analysis of the US prospective open-label study of glatiramer acetate. [2010.03]

Effect of oral antihistamine on local injection site reactions with self-administered glatiramer acetate. [2010.02]

Continuous long-term immunomodulatory therapy in relapsing multiple sclerosis: results from the 15-year analysis of the US prospective open-label study of glatiramer acetate. [2010]

New acute and chronic black holes in patients with multiple sclerosis randomised to interferon beta-1b or glatiramer acetate. [2009.12]

Glatiramer acetate treatment in PPMS: why males appear to respond favorably. [2009.11.15]

Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. [2009.10.31]

Glatiramer acetate has no impact on disease progression in ALS at 40 mg/day: a double- blind, randomized, multicentre, placebo-controlled trial. [2009.10]

Glatiramer acetate in combination with minocycline in patients with relapsing--remitting multiple sclerosis: results of a Canadian, multicenter, double-blind, placebo-controlled trial. [2009.10]

250 mug or 500 mug interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. [2009.10]

Efficacy of treatment of MS with IFNbeta-1b or glatiramer acetate by monthly brain MRI in the BECOME study. [2009.06.09]

Molecular profiling of glatiramer acetate early treatment effects in multiple sclerosis. [2009]

[Long-term effects of glatiramer acetate in multiple sclerosis] [2008.11]

Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial. [2008.10]

Glatiramer acetate after mitoxantrone induction improves MRI markers of lesion volume and permanent tissue injury in MS. [2008.10]

Impact of warm compresses on local injection-site reactions with self-administered glatiramer acetate. [2008.08]

Glatiramer acetate after induction therapy with mitoxantrone in relapsing multiple sclerosis. [2008.06]

Long-term (up to 22 years), open-label, compassionate-use study of glatiramer acetate in relapsing-remitting multiple sclerosis. [2008.05]

Longitudinal magnetic resonance spectroscopic imaging of primary progressive multiple sclerosis patients treated with glatiramer acetate: multicenter study. [2008.01]

Pharmacogenetics of glatiramer acetate therapy for multiple sclerosis reveals drug-response markers. [2007.08]

Long-term follow-up of patients treated with glatiramer acetate: a multicentre, multinational extension of the European/Canadian double-blind, placebo-controlled, MRI-monitored trial. [2007.05]

Randomized, double-blind, dose-comparison study of glatiramer acetate in relapsing-remitting MS. [2007.03.20]

Glatiramer acetate in primary progressive multiple sclerosis: Results of a multinational, multicenter, double-blind, placebo-controlled trial. [2007.01]

During 3 years treatment of primary progressive multiple sclerosis with glatiramer acetate, specific antibodies switch from IgG1 to IgG4. [2006.08]

A prospective open-label study of glatiramer acetate: over a decade of continuous use in multiple sclerosis patients. [2006.06]

Randomized controlled phase II trial of glatiramer acetate in ALS. [2006.04.11]

Effects of oral glatiramer acetate on clinical and MRI-monitored disease activity in patients with relapsing multiple sclerosis: a multicentre, double-blind, randomised, placebo-controlled study. [2006.03]

Neurologic consequence of delaying glatiramer acetate therapy for multiple sclerosis: 8-year data. [2005.01]

Glatiramer acetate (Copaxone): comparison of continuous versus delayed therapy in a six-year organized multiple sclerosis trial. [2003.12]

Effects of glatiramer acetate on relapse rate and accumulated disability in multiple sclerosis: meta-analysis of three double-blind, randomized, placebo-controlled clinical trials. [2003.08]

Copaxone's effect on MRI-monitored disease in relapsing MS is reproducible and sustained. [2002.10.22]

Short-term brain volume change in relapsing-remitting multiple sclerosis: effect of glatiramer acetate and implications. [2001.09]

A prospective, open-label treatment trial to compare the effect of IFN beta-1a (Avonex), IFNbeta-1b (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing-remitting multiple sclerosis. [2001.03]

European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging--measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group. [2001.03]

United States open-label glatiramer acetate extension trial for relapsing multiple sclerosis: MRI and clinical correlates. Multiple Sclerosis Study Group and the MRI Analysis Center. [2001.02]

Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Copolymer 1 Multiple Sclerosis Study Group. [2000.08]

Neuropsychologic status in multiple sclerosis after treatment with glatiramer. [1999.03]

Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group. [1998.03]

Management of relapsing/remitting multiple sclerosis with copolymer 1 (Copaxone). [1996.07]

Well-designed clinical trials possibly related to Copaxone (Glatiramer)

Effects of BG-12 (dimethyl fumarate) on health-related quality of life in patients with relapsing-remitting multiple sclerosis: findings from the CONFIRM study. [2014]

Recruitment of participants to a multiple sclerosis trial: the CombiRx experience. [2014]

Pharmacological treatment for memory disorder in multiple sclerosis. [2013]

A randomized trial of high-dose vitamin D2 in relapsing-remitting multiple sclerosis. [2011.10.25]

A randomized controlled double-masked trial of albuterol add-on therapy in patients with multiple sclerosis. [2010.09]

Results of a phase I study in patients suffering from secondary-progressive multiple sclerosis demonstrating the safety of the amino acid copolymer PI-2301 and a possible induction of an anti-inflammatory cytokine response. [2010.08.25]

Two-year study of cervical cord volume and myelin water in primary progressive multiple sclerosis. [2010.06]

Abnormal B-cell cytokine responses a trigger of T-cell-mediated disease in MS? [2010.04]

Bimonthly assessment of magnetization transfer magnetic resonance imaging parameters in multiple sclerosis: a 14-month, multicentre, follow-up study. [2010.03]

PEGylated interferon beta-1a: meeting an unmet medical need in the treatment of relapsing multiple sclerosis. [2010]

Two-year study of cervical cord volume and myelin water in primary progressive multiple sclerosis. [2010]

Results of a phase I study in patients suffering from secondary-progressive multiple sclerosis demonstrating the safety of the amino acid copolymer PI-2301 and a possible induction of an anti-inflammatory cytokine response. [2010]

Abnormal B-cell cytokine responses a trigger of T-cell-mediated disease in MS? [2010]

A reassessment of the plateauing relationship between T2 lesion load and disability in MS. [2009.11.10]

Effect of anti-IFN{beta} antibodies on MRI lesions of MS patients in the BECOME study. [2009.11.03]

Serum levels of CXCL13 are elevated in active multiple sclerosis. [2009.11]

Serial combination therapy: is immune modulation in multiple sclerosis enhanced by initial immune suppression? [2009.08]

GLANCE: results of a phase 2, randomized, double-blind, placebo-controlled study. [2009.03.03]

Effect of textured foot orthotics on static and dynamic postural stability in middle-aged females. [2008.01]

Cost-Effectiveness Analyses of Natalizumab (Tysabri((R))) Compared with Other Disease-Modifying Therapies for People with Highly Active Relapsing-Remitting Multiple Sclerosis in the UK. [2008]

Outcome measures for early phase clinical trials. [2007.10]

The Timed Up and Go test: predicting falls in ALS. [2007.10]

Clinical and microbiologic changes associated with the combined use of a powered toothbrush and a triclosan/copolymer dentifrice: a 3-year prospective study. [2007.09]

Comparative Efficacy of Stabilized Stannous Fluoride/Sodium Hexametaphosphate Dentifrice and Sodium Fluoride/Triclosan/Copolymer Dentifrice for the Prevention of Periodontitis in Xerostomic Patients: A 2-Year Randomized Clinical Trial. [2007.08]

Clinical and radiographic evaluation of the effects of guided tissue regeneration using resorbable membranes after extraction of impacted mandibular third molars. [2007.02]

Oral hygiene regimens, plaque control, and gingival health: a two-month clinical trial with antimicrobial agents. [2007]

Mycophenolate mofetil in multiple sclerosis. [2004.03]

Interferon beta-1a in primary progressive multiple sclerosis. [2003.02.15]

Short-term correlations between clinical and MR imaging findings in relapsing-remitting multiple sclerosis. [2003.01]

Randomized controlled trials to assess therapies for multiple sclerosis. [2002.04.23]

MRI metrics as surrogate markers for clinical relapse rate in relapsing-remitting MS patients. [2002.02.12]

Copolymer-1. [1997.10]

A review of the clinical efficacy profile of copolymer 1: new U.S. phase III trial data. [1996.04]

Safety profile of copolymer 1: analysis of cumulative experience in the United States and Israel. [1996.04]

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. [1995.07]

Other research related to Copaxone (Glatiramer)

Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis. [2014]

Glatiramer acetate-specific antibody titres in patients with relapsing / remitting multiple sclerosis and in experimental autoimmune encephalomyelitis. [2011.09]

Glatiramer acetate treatment directly targets CD11b(+)Ly6G(-) monocytes and enhances the suppression of autoreactive T cells in experimental autoimmune encephalomyelitis. [2011.09]

Recent insights into the mechanism of action of glatiramer acetate. [2011.06]

Glatiramer acetate could be a hypothetical therapeutic agent for neuromyelitis optica. [2011.06]

Glatiramer acetate in the treatment of multiple sclerosis: emerging concepts regarding its mechanism of action. [2011.05.01]

Beneficial effect of glatiramer acetate treatment on syndecan-1 expression in dextran sodium sulfate colitis. [2011.05]

Glatiramer acetate attenuates neuropathic allodynia through modulation of adaptive immune cells. [2011.05]

Drug adherence and multidisciplinary care in patients with multiple sclerosis: protocol of a prospective, web-based, patient-centred, nation-wide, Dutch cohort study in glatiramer acetate treated patients (CAIR study). [2011.03.30]

Glatiramer acetate treatment of multiple sclerosis: an immunological perspective. [2011.02.15]

Qualitative spectral OCT/SLO analysis of drusen change in dry age-related macular degeneration patients treated with Copaxone. [2011.02]

Patterns of TH1/TH2 cytokines predict clinical response in multiple sclerosis patients treated with glatiramer acetate. [2011]

Glatiramer acetate reduces Th-17 inflammation and induces regulatory T-cells in the CNS of mice with relapsing-remitting or chronic EAE. [2010.08.25]

Glatiramer acetate for multiple sclerosis. [2010.05.12]

Glatiramer acetate and the glatiramoid class of immunomodulator drugs in multiple sclerosis: an update. [2010.05]

Glatiramer acetate: successful desensitization for treatment of multiple sclerosis. [2010.04]

Improved muscle strength and mobility in the dy(2J)/dy(2J) mouse with merosin deficient congenital muscular dystrophy treated with Glatiramer acetate. [2010.04]

Long-term treatment of multiple sclerosis with glatiramer acetate: natural history of the subtypes of anti-glatiramer acetate antibodies and their correlation with clinical efficacy. [2010.03.30]

Glatiramer acetate immune system augmentation for peripheral nerve regeneration in rat crushed sciatic nerve model. [2010.02]

The mechanism of action of glatiramer acetate treatment in multiple sclerosis. [2010.01.05]

Allergy workup in immediate-type local reactions to glatiramer acetate. [2010]

Tolerability and safety of novel half milliliter formulation of glatiramer acetate for subcutaneous injection: an open-label, multicenter, randomized comparative study. [2010]

Glatiramer acetate for multiple sclerosis. [2010]

Effect of oral antihistamine on local injection site reactions with self-administered glatiramer acetate. [2010]

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017